References
- Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc. Drug Rev. 15, 137–156 (1997).
- Pritchett ELC, Schulte MC, Schnell D et al. Azimilide Supraventricular Arrhythmia Program 3 (SVA3) investigators. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation. J. Clin. Pharm. 42(4), 388–394 (2002).
- Pritchett ELC, Marcello SR. Azimilide for •atrial fibrillation: clinical trial results and implications. Cardiac. Electrophysiol. Rev. 7, 215–219 (2003).
- Pritchett ELC, Page RL, Connolly SJ et al. •Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. Antiarrhythmic effects of azimilide in atrial fibrillation. Efficacy and dose response. J. Am. Coll. Cardiol. 36, 794–802 (2000).
- Connolly SJ, Schnell DJ, Page RL et al. ••Dose-response relationships of azimilide in the management of symptomatic, recurrent atrial fibrillation. Am. J. Cardiol. 88(9), 974–979 (2001).
- Page RL, Connolly SJ, Wilkinson WE et al., Azimilide Supraventricular Arrhythmia Program Investigators. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose response. Am. Heart J. 143, 643–649 (2002).
- Camm AJ, Pratt CM, Schwart PJ et al.••Azimilide Post-Infarct Survival Evaluation (ALIVE): azimilide does not affect mortality in postmyocardial infarction patients. Circulation 104(25), 104 (2001).
- Pratt CM, Singh SN, Al-Khalidi HR et al.•Azimilide Post-Infarct Survival Evaluation (ALIVE) investigators. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. J. Am. Coll. Cardiol. 43, 1211–1216 (2004).
- Singer I, Al-Khalidi H, Niazi I et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J. Am. Coll. Cardiol. 43, 39–43 (2004).
- Dorian P, Borggrefe M, Al-Khalidi HR et al. on behalf of the Shock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators. Placebo-controlled, randomized clinincal trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 110, 3646–3654 (2004).